A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 15, Issue 3, 2013, Pages 241-245

  Korsatko, S ^a   Glettler, K ^a   Olsen, K J ^b   Wutte, A ^a   Bock, G ^a   Koehler, G ^a   Mader, J K ^a   Semlitsch, B ^a   Pieber, T R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Larix ApS   (Denmark)

Author keywords

Insulin analogues; Insulin therapy; Pharmacodynamics; Randomized trial; Type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN DETEMIR; INSULIN LISPRO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MUSCLE STRAIN; NAUSEA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; VOMITING;

EID: 84873084241     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12016     Document Type: Article

References (26)

1. Heller S, Kozlovski P, Kurtzhals P. Insulin's 85th anniversary - an enduring medical miracle. Diabetes Res Clin Pract 2007; 78: 149-158.
2. Starke A, Heinemann L, Hohmann A, Berger M. The action profiles of human NPH insulin preparations. Diabet Med 1989; 6: 239-244.
3. Bolli GB, Perriello G, Fanelli CG, DeLeo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 1993; 16(Suppl): 71-89.
4. Yale JG. Nocturnal hypoglycemia in patients with insulin-treated diabetes. Diabetes Res Clin Pract 2004; 65(Suppl. 1): S41-46.
5. Heise T, Nosek L, Rønn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
6. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659.
7. Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007; 30: 2447-2452.
8. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less-variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.
9. Heise T, Weyer C, Serwas A et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-803.
10. Hompesch M, Ocheltree SM, Wondmagegnehu ET et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009; 25: 2679-2687.
11. European Medicines Agency, Committee for Proprietary Medicinal Products Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. 2002. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/108000en.pdf. Accessed 24 April 2012.
12. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 2008; 51: 1790-1795.
13. World Medical Association. 2008. Available from URL: http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 24 April 2012.
14. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog Detemir. Diabetes Care 2005; 28: 1107-1112.
15. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52 week, multinational, randomized, open-label, parallel group, treat-to-target noninferiority trial. Clin Ther 2009; 31: 2086-2097.
16. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002; 41: 1043-1057.
17. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomised, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as ad-on therapy to oral glucose lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274 Erratum in: Diabetes Care 2007; 30: 1035.
18. Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 193-201.
19. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
20. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs morning plus bedtime NPH insulin. Diabet Med 2005; 22: 850-857.
21. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of once-daily insulin detemir or NPH insulin on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
22. De Leeuw I, Vague P, Selam JL et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
23. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin 2006; 22: 2613-2619.
24. 125I-NPH insulin in diabetic patients. Horm Metab Res 1983; 15: 274-278.
25. Jehle PM, Micheler C, Jehle DR et al. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 1999; 354: 307-335.
26. Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naïve patients with type 2 diabetes. Diabet Med 2010; 27: 181-188.